Iovance Biotherapeutics, Inc. (0JDK.L)
USD 7.6
(-2.69%)
USD 7.6
(-2.69%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1 Million USD | -11.22% |
| 2022 | 85.44 Million USD | 19.45% |
| 2021 | 71.53 Million USD | 38.47% |
| 2020 | 51.65 Million USD | 349.21% |
| 2019 | 11.5 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 84.36 Million USD | 11.21% |
| 2024 Q2 | 1 Million USD | -3.18% |
| 2023 Q3 | 79.47 Million USD | -1.53% |
| 2023 Q1 | 83.22 Million USD | -2.6% |
| 2023 Q2 | 80.71 Million USD | -3.02% |
| 2023 FY | 75.86 Million USD | -11.22% |
| 2023 Q4 | 75.86 Million USD | -4.55% |
| 2022 Q4 | 85.44 Million USD | 6.66% |
| 2022 Q3 | 80.11 Million USD | -0.45% |
| 2022 Q2 | 80.47 Million USD | 0.73% |
| 2022 FY | 85.44 Million USD | 19.45% |
| 2022 Q1 | 79.89 Million USD | 11.69% |
| 2021 Q3 | 72.34 Million USD | 38.4% |
| 2021 Q4 | 71.53 Million USD | -1.13% |
| 2021 Q1 | 53.99 Million USD | 19.01% |
| 2021 FY | 71.53 Million USD | 38.47% |
| 2021 Q2 | 52.27 Million USD | -3.2% |
| 2020 Q3 | 3.71 Million USD | 85.46% |
| 2020 Q4 | 45.37 Million USD | 1122.72% |
| 2020 FY | 51.65 Million USD | 349.21% |
| 2020 Q1 | 3.08 Million USD | -27.31% |
| 2020 Q2 | 2 Million USD | -35.2% |
| 2019 Q4 | 4.24 Million USD | -29.4% |
| 2019 Q3 | 6.01 Million USD | 30.44% |
| 2019 Q2 | 4.61 Million USD | 5.32% |
| 2019 Q1 | 4.38 Million USD | 0.0% |
| 2019 FY | 11.5 Million USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | -100.0% |
| 2013 Q1 | 6.78 Million USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | 97.263% |
| Dynavax Technologies Corporation | 256.91 Million USD | 99.611% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 97.592% |
| Perrigo Company plc | 4.07 Billion USD | 99.975% |
| Illumina, Inc. | 2.26 Billion USD | 99.956% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.997% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.99% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.993% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 99.424% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.963% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 96.295% |
| Waters Corporation | 2.35 Billion USD | 99.958% |
| Biogen Inc. | 7.33 Billion USD | 99.986% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 97.376% |
| Evolus, Inc. | 126.54 Million USD | 99.21% |
| Adicet Bio, Inc. | 17.7 Million USD | 94.351% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 97.683% |
| bluebird bio, Inc. | 330.32 Million USD | 99.697% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.815% |
| FibroGen, Inc. | 170.45 Million USD | 99.413% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.963% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 95.212% |
| Homology Medicines, Inc. | 44.05 Million USD | 97.73% |
| Geron Corporation | 85.89 Million USD | 98.836% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 99.958% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 99.775% |
| Myriad Genetics, Inc. | 145 Million USD | 99.31% |
| Viking Therapeutics, Inc. | 1.26 Million USD | 20.635% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 99.133% |
| Zoetis Inc. | 6.8 Billion USD | 99.985% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 77.283% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.954% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 99.912% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 99.876% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 97.247% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 99.931% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 98.272% |
| Verastem, Inc. | 41.55 Million USD | 97.594% |
| Nektar Therapeutics | 230.4 Million USD | 99.566% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 99.463% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 67.469% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 99.928% |
| OPKO Health, Inc. | 326.56 Million USD | 99.694% |
| Exelixis, Inc. | 189.94 Million USD | 99.474% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.767% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -562.252% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 99.278% |
| Imunon, Inc. | 1.13 Million USD | 12.226% |
| Blueprint Medicines Corporation | 774.12 Million USD | 99.871% |
| Insmed Incorporated | 1.2 Billion USD | 99.917% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.933% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 98.245% |
| TG Therapeutics, Inc. | 110.79 Million USD | 99.097% |
| Incyte Corporation | 38.28 Million USD | 97.388% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 99.886% |